It is estimated that 20000 to 30000 new patients are diagnosed with osteonecrosis annually
accounting for approximately 10% of the 250000 total hip arthroplasties done annually in the …

Osteonecrosis of the femoral head may lead to progressive destruction of the hip joint.
Although the etiology of osteonecrosis has not been definitely delineated, risk factors …

Osteonecrosis of femoral head (ONFH) is a disabling condition of young individuals with ill-
defined etiology and pathogenesis. Remains untreated, about 70–80% of the patients …

Symptomatic hip osteonecrosis is a disabling condition with a poorly understood aetiology
and pathogenesis. Numerous treatment options for hip osteonecrosis are described, which …

Introduction Stem cell therapy with bone marrow-derived mononuclear cells (BMMCs) is an
option for improving joint function in osteonecrosis of the femoral head (ONFH). Bone …

Osteonecrosis, a form of ischemic bone injury that leads to degenerative joint disease,
affects∼ 30% of people with sickle cell disease. Although osteonecrosis most commonly …

Background Total hip arthroplasty is the most widely used procedure to treat avascular
necrosis (AVN) of the femoral head. Few studies have compared the outcomes of THA in …

Sickle cell disease (SCD) is an inherited haemoglobin disorder, associated with recurrent
painful episodes, ongoing haemolytic anaemia and progressive multi-organ damage. Until …

Osteonecrosis (ON) of the hip, with its varied causes and poorly understood pathogenesis, is
an incapacitating disease primarily affecting the active population in the third and fourth …

Polymerization of HbS and cell sickling are the prime pathophysiological events in sickle cell
disease (SCD). Over the last 30 years, a substantial understanding at the molecular level …